First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
Crossref DOI link: https://doi.org/10.1007/s00280-017-3516-1
Published Online: 2018-01-11
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wang, Shuyun
Gao, Aiqin
Liu, Jie
Sun, Yuping
Funding for this research was provided by:
National Natural Science Foundation of China (81372334)
Natural Science Foundation of Shandong Province (CN) (ZR2017PH076)
License valid from 2018-01-11